Manish Kapadia
Pulmonary Disease · Port Charlotte, FLNPI 1205865615
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Intuitive Surgical at 32.6% of the total. Reporting peaked in 2022 at $1,855 and has fallen 93.4% since, to $122 in 2025. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 105 payments — averaging $34.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- Johnson & Johnson$543
- Actelion Pharmaceuticals US, Inc.$494
- Regeneron Healthcare Solutions, Inc.$323
- Jazz Pharmaceuticals Inc.$189
- AstraZeneca$180
- plus $703 from 15 others
What the payments were for
- Travel & lodging$1,33037%
- Food & beverage$2,14359%
- Education$1314%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $1,173 |
| Johnson & Johnson(2 entities) | 8 | $543 |
| Actelion Pharmaceuticals US, Inc. | 19 | $494 |
| Regeneron Healthcare Solutions, Inc. | 16 | $323 |
| Jazz Pharmaceuticals Inc. | 5 | $189 |
| AstraZeneca | 12 | $180 |
| Boehringer Ingelheim | 5 | $92 |
| Paratek Pharmaceuticals, Inc. | 4 | $80 |
| GSK | 5 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| Genentech USA, Inc. | 4 | $75 |
| Novartis | 4 | $74 |
| Bayer | 3 | $50 |
| Boston Scientific | 1 | $42 |
| Optinose US, Inc. | 1 | $23 |
| United Therapeutics Corporation | 1 | $20 |
| Merck | 1 | $19 |
| Harmony Biosciences LLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$847
- Monarch Platform$465
- UPTRAVI$125
- OPSUMIT$125
- RYLAZE$122
How this compares
$3,605 in reported general payments places this provider in the 50th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Port Charlotte
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.